HIF1A (Hypoxia inducible factor 1, alpha subunit)

Therefore, in this review, we explore the multiple pathways through which the Trx system influences HIF-1α and highlight drugs that have been studied targeting hypoxia-related factors by inhibiting the Trx system. Given the link between oxidative stress and apoptosis in cancer cells, and the low overall survival rates for many cancers despite new therapies, understanding the Trx system's connection to hypoxia-related pathways could be crucial for advancing therapeutic approaches and tackling therapy resistance.

Disrupting the CLOCK-TFPI2 interplay through dual inhibition of their downstream effectors reduces GSC stemness and immunosuppressive microglia, activates antitumor immunity, and synergizes with anti-PD1 therapy to achieve complete tumor regression in 50-62.5% of tumor-bearing mice. This study uncovers a promising therapeutic strategy for a broader subset of GBM patients with high expression of either CLOCK or TFPI2, and provides a framework for identifying 'symbiotic exclusivity' genes in cancer.

Although these interventions demonstrate strong preclinical efficacy, translation to consistent clinical benefit remains limited, partly due to inadequate hypoxia biomarkers and insufficient preclinical models that fail to replicate tumor oxygen gradients. Future progress will require biomarker-guided patient selection, optimized combination regimens, and early clinical evaluation of oxygen-delivery platforms to enhance cisplatin sensitivity and reduce hypoxia-driven chemoresistance.

The tumor proliferation was effectively inhibited, and its volume has reduced to 3% of the original solid tumor in the in situ transplantation tumor model. This work presents Pt/SnO2-x@PDA@CaP-GOx as a highly effective X-ray-responsive radiosensitizer, offering a promising strategy for TNBC radiotherapy.

Survival analysis revealed significantly prolonged survival without systemic toxicity. Collectively, tLyP-NPs represent a promising multifunctional nanoplatform that integrates BBB penetration, TME-responsive drug release, and synergistic chemo-gene therapy for GBM treatment.

Meanwhile, the inhibitory effects induced by knockdown of PVT1 on osteoclast differentiation and inflammation were reversed by elevating HIF-1α. These data uncover that elevated expression of PVT1, regulated by METTL3-mediated m6A modification, activates the HIF-1α/RANKL pathway, thereby exacerbating osteoclast activation in SpA-induced OM.

The elevated ROS production significantly improves PDT efficacy and, in combination with mPTT, potentiates the ICD of tumor cells. Overall, this strategy offers a significant advancement in cancer immunotherapy by improving the tumor microenvironment and enhancing immune activation.

Potential essential amino acid residues included leucine 264, tryptophan 80, lysine 268, valine 270, threonine 211, and leucine 210. In conclusion, these findings provide computational evidence supporting the predicted underlying mechanisms, bioactive compounds, and targets potentially associated with the anticancer effects of onion peels in PCa development, although further experimental validation may be necessary.

Inhibitor-treated cells acquire metabolic characteristics clearly distinct from untreated cells, triggering compensatory mechanisms that must be considered for the secondary treatment of glioma with temozolomide. The induction of oxidative stress and metabolic rearrangement play key roles in the cytotoxic effect of the miRNA675-5p inhibitor, which could be proposed as a new therapeutic approach in glioma.

Furthermore, mice treated with 27OHC exhibited reduced exercise endurance, decreased muscle cross-sectional area, and impaired muscle recovery following barium chloride-induced injury. As plasma levels of 27OHC are increased in elderly individuals, our findings suggest that pharmacological inhibition of 27OHC generation could be a therapeutic strategy to treat age-related muscle atrophy.

We further showed that 106 reduced lactate and ATP levels and induced markers of apoptosis, including increased p-AMPK/AMPK ratio and increased Bax levels, as well as decreased Bcl2 levels. Collectively, our findings highlight the potential of GCVec in identifying 106, a first in class dual-function HK2i which emerges as a promising lead compound for further development into a possible anticancer therapeutic agent.

Notably, TPM3 inhibition synergised with Paclitaxel and Doxorubicin, enhancing therapeutic efficacy. In addition, TPM3 was incorporated into extracellular vesicles (EVs), with hypoxia increasing EV-mediated transfer of TPM3 to normoxic cells and promoting their motility. These findings establish TPM3 as a hypoxia-inducible, HIF-1-regulated effector of cytoskeletal dynamics and intercellular communication, underscoring its potential as a therapeutic target to limit TNBC aggressiveness and improve treatment outcomes.